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AVOIDING CATASTROPHIC DRUG TOXICITIES:  AACC  July 22, 2009“If it were not for the great variability among 
individuals, medicine might as well be a science and 
not an art”
Sir William Osler, 1892
Genetics & Adverse Drug ReactionsPersonalizing Medicine= defining optimal diagnostic, management & 
treatment strategies for the individual patient
Pharmacogenetics Pharmacoecology
-specific tests to prevent 
toxicity (eg. HLA-B*5701 
screening for abacavir 
hypersensitivity
-guide dosing of drugs
-HLA and other immune 
markers to guide vaccine 
development and predict 
response
-individualizing the patient’s environment to 
optimize therapeutic outcome
-PK/PD interactions with drugs, herbal medicines 
and nutritional supplements
-food effects on drugs (absorption/bioavailability)
-adherence (cultural & socioeconomic influences)
-intercurrent disease of host state (eg organ failure, 
pregnancy)
-diurnal variation in pharmacokinetics/dynamics
-individual drug taking behaviour
Personalized Prescription
Phillips E, Mallal S   Personalized  Medicine 2009, 6(4), 393-408Goals
• Define drug hypersensitivity reactions by 
epidemiological and immunological classifications 
and how these fit into broader context of adverse 
drug reactions
• Discuss new insights into the pharmacogenetics of 
drug hypersensitivity reactions
• Discuss clinical applications of pharmacogenetics
to prevent drug hypersensitivity and the associated 
hurdlesCharacteristics of Drug Reactions
Classification TYPE A = 
Pharmacological
TYPE B = 
“Bizarre”
Predictable Yes No
Dose Dependent +++ + 
Host Dependent
(Genetic factors)
+ +++
Immunologic basis - +++
Examples Gastrointestinal 
intolerance, seizures with 
penicillin etc
Allergic and 
idiosyncratic 
syndromes, 
hypersensitivity 
syndromesClassification of ADRs
Drug Reaction
Predictable Reactions
(dose dependent)
Unpredictable Reactions
(less dose dependent)
Gell Coombs             Pseudoallergic
Type I ASA
Type II Vancomycin
Type III Contrast
Type IVa-d
Clinical Syndromes
•Reactive
Metabolite
Syndromes
(eg, Drug 
Hypersensitivity
Syndrome)
•Hepatitis
•SJS/TEN
“IDIOSYNCRATIC”TYPE B REACTIONS: Associated Drugs
Anticonvulsants
 phenytoin, phenobarbital, carbamazepine
 lamotrigine
Antimicrobials
 sulfonamides (sulfa antimicrobials), penicillins, dapsone
 nitrofurantoin, minocycline, metronidazole
Allopurinol
Antiinflammatories (eg oxicam-NSAIDS, Valdecoxib)
Antiretrovirals
Alternative medicines 
 Chinese herbals etc.
Antineoplastics
mAbs 
 “Ximab” (infliximab, rituximab) > “Zumab” (omalizumab) > 
“Mumab”(adalimumab)Pharmacogenetics
Drug  Disease  Gene
Dose Dependent Disease
-Drug Efficacy or toxicity 
-Often multifactorial (eg age, gender, BMI, 
concurrent medications)
-Often related to polymorphism(s) in drug 
metabolizing enzymes (eg CYP) or 
pharmacodynamic factors
-eg Warfarin, efavirenz, clopidogrel               
Dose Independent Disease
-HLA & Drug Hypersensitivity
1abacavir hypersensitivity (HLA-B*5701)
2carbamazepine SJS/TEN (HLA-B*1502)
phenytoin SJS/TEN (HLA-B*1502)
3allopurinol SJS/TEN/HSR(HLA-B*5801)
4ximelagatran hepatotoxicity (HLA-
DRB1*07; DQA1*02
5nevirapine rash and rash associated 
hepatitis (class I (HLA-DRB1*0101 + CD4+, 
HLA-B*1402, HLA-Cw8, HLA-B*3505)
6Flucloxcacillin cholestatic liver disease 
(HLA-B*5701)
TYPE A TYPE B
1Mallal S et al Lancet 2002;359;727-32
2Chung WH et al. Nature 2004;428:486
Locharenkul et al Epilepsia 2008;49:2087-91
3Shuen-lu Hung et al PNAS 2005;102:4134-9
4Kindmark et al. Pharmacogenomics J 2008;8:186-95
5Martin & al. AIDS 2005;19:97-99; Littera et al. AIDS 2006;1621-6; Gatanga 
H et al AIDS 2007;21:264-5; Vitezica et al AIDS 2008;540-1; Chantarangsu 
et al Pharmacogent Genomics 2009;9:139-46.
6Daly et al. Nature Genetics. Published online May 31, 2009HLA & Drug Hypersensitivity
Lancet March 30, 2002
Lancet March 2, 2002Nature 2004
Chung et al Nature 2004;428:426Carbamazepine FDA Label Change December 2007
• HLA-B*1502 prevalent in 
Han Chinese (10-15%) vs
Caucasians (<0.1%)
• Not predictive for 
development of 
carbamazepine SJS/TEN in 
Caucasian population*
*Alfirevic et al 
Pharmacogenomics 2006;7:813Other Aromatic Amine 
Anticonvulsants?......
*Clinical cross-reactivity occurs in 
approximately 70-80%
Epilepsia 2008;49:2087-91
-HLA cross-reactivity is not completeMarch 15, 2005 (4134-9)
-HLA-B*5801 present in 9-11% Han Chinese but also present in other 
races (Caucasian 1-6%; African 2-4%; Japanese <0.4%)
-Some studies suggest some generalizability across European and 
Japanese populationspublished online May 31 2009
-Strong association but only small proportion of HLA-B*5701 positive 
patients will develop flucloxacillin DILI
-Extremely low positive predictive value (1.26%) therefore assuming 
Caucasian population carriage rate of HLA-B*5701 of 6-8% would need to 
screen over 1000 patients to prevent one case 
-Other factors (off chromosome 6) may be important  (ST6GALI which 
encodes sialic acid transfer enzyme)Associations may differ across race, phenotype, 
study design and underlying immune status
• HLA-DRB1*0101 + CD4% > 25 and rash 
associated hepatitis (Martin et al AIDS 2005)
• HLA-Cw8-B14 haplotype in Sardinians (Littera et al 
AIDS 2006)
• HLA-Cw8 in Japanese (Gatanaga et al AIDS 2007
• HLA-DRB1*01 in French population with efavirenz
or nevirapine rash
Pharmacogenetics & Genomics 2009NEVIRAPINE 
HYPERSENSITIVITY
(rash of varying severity, fever, 
hepatitis, multisystem disease)
Sufficient levels of relevant metabolite
(distinct from dose dependent or “Type A” adverse drug reactions)
•Nevirapine disposition (?Role of CYP3A4/CYP2B6/CYP2C9) and drug transporters (P-glycoprotein(MDR1)) and 
polymorphisms in drug metabolizing and drug transporter genes that differ across ethnicity
Genetic susceptibility conferred by 
Class I  MHC marker(s) eg. HLA-
B*1402, HLA-Cw8, HLA-B*3505
Genetic susceptibility conferred by Class II MHC 
marker(s) eg.  HLA-DRB1*0101
+ Sufficient levels of CD4+ T cells 
•Class II-restricted immune response to NVP-
specific antigen
Class I-restricted immune response to 
NVP-specific antigen
OR
Phillips E, Mallal S.  Current Opinion in Molecular Therapeutics 2009; 11(3);231-242Host-Drug-Infection Interactions: 
A Complex Dynamic
HOST
PATHOGEN DRUG
HLA
Immune response 
genes
Control of infection
Vaccine design
Pharmacodynamics
Pharmacokinetics
Drug Efficacy
Drug Toxicity
Drug resistance
Drug  Efficacy
Chronic persistent DNA 
viruses (CMV, EBV, HHV-
6, Herpes viruses) and/or  
HIVClassic 3 ring Target – HSV not drug
Mucositis & Atypical target
Atypical Target – 2 ring
dusky center 
Blistering of TENHLA-B*1502 & Carbamazepine: 
Phenotype is Important
-associated with severe skin syndromes (SJS/TEN in Han Chinese)
-NOT associated with drug hypersensitivity (fever/rash/internal organ 
involvement)  or ?disease in Caucasians
Stevens-Johnson Syndrome/Toxic Epidermal NecrolysisDrug Hypersensitivity & HLA:  
Immunogenetic Models
Carbamazepine Abacavir
Class I MHC
HLA-B*5701
Specific for disease 
(SJS/TEN) & Race 
(Han Chinese)
Class I MHC
HLA-B*1502
CD8+
Nevirapine
Class I 
MHC
Class 
II MHC
CD8+ CD4+
Metabolic differences 
between race driving 
differences in 
phenotype
CD8+
Specific for disease, 
generalizable
across racePrerequisites for Widespread 
Incorporation of HLA 
Pharmacogenetic Testing
Implications differ according to drug…Phillips E, Mallal S, Current Opinion in Molecular Therapeutics 2009;11:231-42Translating Research in Genomic Medicine into the Clinic & Beyond
• STEP 1 – The discovery & turning 
this into a health application
• STEP 2 - Development of high level 
clinical evidence (randomized) in 
support of test. Basic science to 
support biological plausibility
• STEP 3 - Diffusion of research and 
delivery to clinic depends on 
efficiency and quality assurance of 
laboratory testing and reporting
• STEP 4 – Evaluating performance of 
the test in real clinical practice 
2002 – HLA-B*5701 association in two 
independent groups
2002-present: genetic and cellular 
studies support plausibility of 
association
2005-2008 – PREDICT-1, SHAPE & 
observational studies provide robust 
clinical evidence
2005 - PCR-based techniques readily 
applicable methodology (rapid, 
inexpensive) 
2005-2008 - HLA-B*5701 quality 
assurance program roll-out
2008 – HIV Treatment 
guidelines/product information change 
to incorporate recommendation for 
baseline testing & reimbursement
2008 + - Multiple observational studies 
Pharmacoeconomic evaluation
Post “PREDICT-1” clinical quality 
assurance
Imprecision of clinical phenotype (false positive clinical diagnosis) cast doubt on 
generalizability of HLA-B*5701 to “all” abacavir HSR. Patch testing developed to identify 
those with true immunologically medicated HSR
Phillips E, Mallal S  Personalized Medicine 2009;6:393-408Predicting Drug Hypersensitivity in Clinical 
Practice:  The Abacavir Example
• Guanosine nucleoside analogue used in antiretroviral therapy, approved 
by regulatory agencies 1998/1999
• Hypersensitivity syndrome characterized by fever, malaise +/- skin rash 
was characterized in pre-marketing phase, not fatal unless drug 
reintroduced; affected approximately 6- 8% of predominantly Caucasian 
population
• Robust clinical management program for drug
• Early clues such as familial case reports and rarity in Blacks suggested 
genetic association
• 2002 – two independent groups reported strong association with HLA-
B*5701
• 2008 – screening for hypersensitivity has rolled out into much of 
developed worldHLA-B*5701 and Abacavir 
Hypersensitivity: A Comparison 
of Two Studies
*Caucasians only
Observed sensitivity and specificity
PV assumes prevalence of ~9%
Pos Neg
Mallal et al, 2002
HLA-B*5701
Hetherington et al, 2002*
HLA-B57
14 4
5 177
Pos PV Neg PV
74% 98%
HSR
No HSR
Sens 78%
Spec 97%
Pos Neg
36 29
8 649
Pos PV Neg PV
82% 96%
Sens 55%
Spec 99%
Mallal, et al. Lancet 2002;359:727-2.
Hetherington, et al. Lancet 2002;359:1121-2.Early Problems with “Phenotype” 
0
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Mallal CNA30027 CNA30032
White Black
78% 
57%
48%
8%
•Early studies have observed variable sensitivity of 
HLA-B*5701
-Definition of abacavir hypersensitivity reaction (ABC HSR)
nonspecificity of clinical phenotyping 
false positive clinical diagnosis
-Differences in white and nonwhite races
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Mallal et al. Lancet 2002
Hughes et al.  Pharmacogenomics 2004Phenotypic Uncertainty of Abacavir HSR
Blinded Study Abacavir 
Groups
Zidovudine or 
indinavir
CNA3005 19/268 (7%) 6/265 (2%)
CNA30024 27/324 (8%) 10/325 (3%)
Total Cases 46/592 (7.8%) 16/590 (2.7%)
Cases in CNA30024 as reported by Investigators in the ABC HSR 
CRF Module
Hernandez, et al. ADR/Lipodystrophy 2003.Patch Testing Following Abacavir (ABC) Exposure
Presentation by epidermal Langerhans cells
Sensitization
Local Reaction
ABC  Reactive Metabolite (Antigen)
Alcohol dehydrogenase 
(Abacavir)
Conjugation with host protein in skin
CYP450
CD8+
Prior ABC
ingestion
Day 0 >6 weeks later
Phillips et al  AIDS 2002;16:223, Phillips et al AIDS 2005;19:979. Phillips E, 
Mallal S.  Mol Diag Ther 2009;13:19Abacavir Skin Patch Testing
3 previously assigned cases had diagnosis revised
(1) Concurrent NNRTI therapy
(2)  Negative patch test
Patch testing
Previously assigned cases
Carriers of 57.1 AH markers  9/9
Non-57.1 carriers (NNRTI+)  0/3   
Non-57.1 carriers (NNRTI-)  1 patient 
unavailable
ABC HSR
ABC non-HSR Previously assigned tolerant
Carriers of 57.1 AH markers        0/5
Martin, et al. PNAS 2004;23;101:4180-5.HLA-B*5701 and Abacavir 
Hypersensitivity
Reclassified first 200 patients (*not available)
Martin, et al. PNAS 2004;23;101:4180-5.
Pos Neg
HLA-B*5701
15 1*
4 180
Pos PV Neg PV
78.9% 99.4%
Sens 93.8%
Spec 97.8%
HSR
No HSRPatch Testing
• Useful for abacavir to phenotype patients with true immunologically 
mediated abacavir hypersensitivity
• NOT a predictive test: patients need previous systemic exposure to 
abacavir
• Diagnostic sensitivity (from PREDICT-1) = 87%
• Useful in practice to identify novel HLA allele associated abacavir
hypersensitivity but NOT to rechallenge patients with clinical history 
consistent with abacavir hypersensitivity
• Sensitivity in other drug hypersensitvities (eg carbamazepine) appears 
much lower (50% or less)
• Positive in 30-50% of other drug associated disease (eg fixed drug 
eruption, acute generalized exanthematous pustulosis)
Shear  et al .  AIDS 2008;22:999-1007Incorporation of a Pharmacogenetic Test 
into Clinical Practice
• High level evidence generalisable to diverse clinical 
settings
• Widespread availability of cost-effective and 
reliable laboratory tests
• Effective strategies to operationalise testing into 
routine clinical practice*P<0.05
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Possible abacavir-related 
symptoms, number of patients
(including definitive ABC HSR)
Abacavir HSR, number of 
patients
# 2 pts results not reviewed prior
therapy
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n=68 n=131 n=107 n=60
#
Before genetic screening After genetic screening
#$ 
Fall in Early Discontinuation of Abacavir after 
Introduction of Prospective Genetic Screening*
Rauch, et al. Clin Infect Dis 2006;43:99-102.
*p<.05
-HLA-B*5701 
Screening eliminated 
true  and false 
positive abacavir 
hypersensitivity  
BUT NEED TO HAVE 
GOOD 
COMMUNICATION 
BETWEEN 
HEALTHCARE 
TEAM AND CHECK 
HLA-B*5701 
RESULTS PRIOR TO 
STARTING 
ABACAVIR!!!!!Other Observational Data
*Trottier et al  abacavir early discontinuation decreased from 13.6% to 5.6% after 
screening, IAS 2007, abstract MOPEB002)
+HLA-B*5701 + HSR from 12.2% to 0% (Zucman et al JAIDS 2007; epub March 8)
^ABC HSR 6.5% historically to 0% post screening (Reeves et al HIV Medicine March 
2006)
*
0.00%
5.00%
10.00%
15.00%
Prescreen Postscreen
Brighton
France
Canada
CanadaAbacavir Hypersensitivity in Clinical Trials
*All 4/725 (0.8%) patients in ARIES study clinical diagnosed with 
HSR were patch test negative
Wannamaker P et al, World AIDS, Mexico City, AIDS 2008;22(13):1673-5• First RCT to look at clinical utility of a 
pharmacogenetic test to prevent a specific drug 
toxicity
• Problem of false positive clinical diagnosis of 
abacavir hypersensitivity was over come by using 
strategy of skin patch testing (100% specific) to 
define the phenotype of true immunologically 
mediated abacavir hypersensitivity
N Eng J Med 2008;358:568-79Prospective, randomized (1:1), double-blind, multicenter study with 6-week 
observation period (>90% of HSR cases)
ABC-naive
subjects (n=1956)
1:1 Randomization
ABC was the only required drug for this study; 
Remainder of regimen was investigator-selected
Patients start ABC (n=913); 
Samples tested for HLA-B*5701
at the end of the study
Only HLA-B*5701-
subjects 
start  ABC (n=859)
HLA-B*5701+ subjects 
excluded from 
study (n=54)
No screening
(n=976)
Samples tested 
for HLA-B*5701
in real time 
(n=980)
If HSR occurs, 
undergo patch 
test 6-8 weeks 
after event
CONTROL
SCREENING 
PREDICT-1
Mallal S et al N Eng J Med 2008;358:568-790
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%
)
3.4%
(27/803)
7.8%
(66/847)
2.7%
(23/842)
OR 0.40
P < 0.0001
OR 0.03
P < 0.0001
Control arm
Prospective HLA-B*5701
screening arm
Clinically Suspected
HSR
Immunologically Confirmed
HSR
Clinically Suspected and 
Immunologically Confirmed HSR 
in ITT evaluable population
0.0%
(0/802)
(0.25, 0.62)
(0, 0.18)Abacavir Exposed >6 weeks 
100%
Clinically suspected 
HSR  7.8%
Patch +‘ve 
HSR  2.7%
HLA-B*5701 +’ve  
‘True’ HSR (3.1%)
HLA-B*5701 +’ve 
ABC Tolerant (2.6%)
N Eng J Med 2008;358:568-
79
Phillips E, Mallal S 
Personalized Medicine 
2009, 6(4), 393-408INDIA  5-20%
JAPAN  0%
CHINA  0%
(NB 2.5% N.E. 
provinces)
UK 
~8%
MIDDLE EAST  1-2%         
(NB 5-7% Ashkenazi Jews)
AUSTRALIA 
~8%
US 
Caucasian 
~8%
US Asian 
~1%
US 
African-
American 
~2.5%
W. EUROPE  5-7%
THAILAND 
4-10%*
*THAILAND B*57 carriage:
Urban Bangkok 3.6%
Thai Dai Lue (NE Thai) ~11%
Southern Thai Muslim 3%
MEDITERRANEAN 
1-2%
S. AMERICAN 
Caucasian  
5-7%
US 
Hispanic 
~2%
Subsaharan 
AFRICA
<1%
HLA-B*5701 Carriage Frequency
Phillips E, Clin Infect Dis 2006.SHAPE Study Design
Black and White subjects 
with clinically-suspected
ABC HSR (CS-HSR)
ABC
skin patch test 
& HLA-B*5701
Negative
CASES
Positive
White: 130
Black: 69
White: 42
Black: 5
White: 85
Black: 63
HLA-B*5701 results available for all but one case
Skin patch test results unavailable for 3 Whites, 1 Black
White: 202
Black: 206
HLA-B*5701 results available for all control subjects
Black & White subjects 
enrolled in KLEAN, ALOHA,
CNA30027, CNA30032
Identify ABC-tolerant
subjects who provided
PGx consent and sample
CONTROLS
Black & White subjects 
enrolled in KLEAN, ALOHA,
CNA30027, CNA30032
CONTROLS
Identify ABC-tolerant
subjects who provided
PGx consent and sample
*Saag et al Clin Infect Dis 2008;46:1111-18High Negative Predictive Value of HLA-
B*5701 Generalised Across Race
SPT-pos
(n=42/42)
100%
CS-HSR
(n=57/130)
44%
Control
(n=194/202)
96%
SPT-pos
(n=5/5)
100%
CS-HSR
(n=10/69)
14%
Control
(n=204/206)
99%
White Black
S
e
n
s
i
t
i
v
i
t
y
/
S
p
e
c
i
f
i
c
i
t
y
 
 
o
f
 
H
L
A
-
B
*
5
7
0
1
a
n
d
 
9
5
%
 
C
I
OR: White   IC-HSR 1945 [110-34352]; CS-HSR 19[8-48] Black   IC-HSR 900 [30-21045]; CS-HSR 17[4-164]DHHS Guidelines:  http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf: Jan 2008.
IAS Guidelines:  JAMA 2008;300(5):555-70
Preferred
NNRTI EFV ABC/3TC (for HLA-B*5701 negative patients) or
TDF/FTC
PI FPV/r BID
LPV/r BID
ATV/r
ABC/3TC (for HLA-B*5701 negative patients) or
TDF/FTC
Major Treatment Guidelines Revised to 
Reflect HLA-B*5701 ScreeningPharmacogenetics and HLA: 
Predicting the Unpredictable?
• Type A reactions are predictable based on their 
pharmacological action therefore pharmacogenetic factors 
will only explain a proportion of the variability in drug 
response
• Type B adverse drug reactions such as hypersensitivity 
reactions and severe skin syndromes are 
immunogenetically mediated 
• HLA associations are promising for prediction and hence 
prevention of these types of reactions but abacavir is 
currently the only drug where high level evidence exists and 
widespread screening has been implemented
• Numerous clinical and laboratory hurdles must be overcome 
for successful integration of pharmacogenetic testing into a 
clinical setting.Acknowledgments
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